HDP 15.0022 is an ´Enhanced Pro-Drug of Clofarabine´. This patent protected new chemical entity was derived from the nucleoside Clofarabine using the company's proprietary EPD Technology.

Clofarabine received FDA marketing approval for pediatric and relapsed or refractory acute lymphoblastic leukaemia in December 2004. Clofarabine has also demonstrated activity in acute leukaemia in phase l and phase ll clinical trials. The clinical development of Clofarabine for the treatment of solid tumors was discontinued because of severe myelosuppression, necessitating dose-deescalation to levels without clinical efficacy.

Pre-clinically, HDP 15.0022 is significantly more effective than Clofarabine and lacks its severe myelosuppression. Heidelberg Pharma expects EPD-Clofarabine to provide a new potent anti-cancer drug for once-a-day oral administration.